Bharat Biotech International Limited (BBIL), the manufacturer of iNCOVACC (BBV154), has received emergency restricted use approval for persons aged 18 years and over in India for heterologous booster doses.
The vaccine manufacturer said in a statement: “iNCOVACC is a recombinant replication-deficient adenovirus vectored vaccine with a stabilized SARS-CoV-2 spike protein prior to fusion. This vaccine candidate was evaluated in Phase I clinical trials.” , II and III with successful results.”
“iNCOVACC has been specifically formulated to allow intranasal delivery via nasal drops. The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries.”
According to Bharat Biotech, iNCOVACC was developed in partnership with Washington University in St. Louis, which had designed and developed the recombinant adenovirus-vectored construct and evaluated it in preclinical studies for efficacy. ■